Tipelukast - MediciNova
Alternative Names: KCA-757; MN-001Latest Information Update: 18 Aug 2023
At a glance
- Originator Kyorin Pharmaceutical
- Developer MediciNova
- Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Hepatoprotectants; Small molecules
- Mechanism of Action 5-lipoxygenase inhibitors; Leukotriene D4 receptor antagonists; Leukotriene receptor antagonists; Phospholipase C inhibitors; Thromboxane A2 receptor antagonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- No development reported Interstitial cystitis
- Discontinued Asthma
Most Recent Events
- 15 Aug 2023 MediciNova receives patent allowance for Tipelukast in Europe for the treatment of scleroderma and/or systemic sclerosis
- 14 Aug 2023 MediciNova receives notice of intention to Grant from the European Patent Office for Tipelukast for Nonalcoholic steatohepatitis in EU
- 30 Apr 2023 MediciNova receives notice for patent allowance for Tipelukast for Nonalcoholic steatohepatitis in Canada